+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Local Anesthesia Drugs Market - Growth, Trends and Forecast 2017 - 2022

  • ID: 4388599
  • Report
  • Region: Global
  • 211 pages
  • Mordor Intelligence
1 of 3
The global local anesthesia drugs market accounted for a market value of USD 8,160 million in 2015 and is expected to reach USD 8,335 million in 2016. The market is expected to reach USD 9,240 million by 2021, growing at a CAGR of 2.1% during the forecast period of 2016 to 2021. Local anesthetics functions by blocking the generation and the conduction of nerve impulses. The blocking is mostly done by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the action potential. The effect and progression of anaesthesia is mostly related to the diameter, myelination and conduction velocity of affected nerve fibres. The order by which the nerve loses its functionality will be as follows: pain, temperature, touch, proprioception and skeletal muscle tone.

The common drugs in local anaesthetics can be chemically classified as: a) Ester linked Local Anesthetics like Cocaine, Procaine, Chloroprocaine, Tetracaine, benzocaine and others. b) Amide linked Local anesthetics such as Lidocaine, Bupivacaine, dibucaine, prilocaine, ropivacaine and others.

Increase incidences of surgeries, trends in cosmetic surgery procedures, increasing dental procedures, plastic surgery and lesser side effects compared to general anaesthetics are the primary drivers that is propelling the growth of the market.

In this report the global local anesthesia drugs market have been segmented based on drugs, applications, and geography. The drugs market have been segmented into Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Oxethazaine, Prilocaine, Benzocaine and other local anesthetics. The segment based on application includes plastic and cosmetic surgery, Dental anesthesia, spinal anesthesia, peripheral nerve block, epidural, interscalene block, saddle block, and others. Ropivacaine accounted for the largest market share in 2015.

The segmentation based on geography includes North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The North America have been subdivided into USA, Canada and Mexico. The Europe have been subdivided into UK, Germany, France, Italy, Spain, and rest of Europe. The Asia-Pacific market have been subdivided into India, China, Japan, South Korea, Australia & New Zealand and rest of Asia-Pacific. The Middle East and Africa market have been subdivided into GCC countries, South Africa and rest of MENA. The South American market have been subdivided into Brazil, Argentina and rest of South America. The North America accounted for the largest market share in 2015.

The key players in the market AstraZeneca, Fresenius Kabi, Teva Pharmaceuticals, Hospira, Sagent Pharmaceuticals, Mylan, and Actavis.

Key Deliverables:

Market analysis for the Global General Anesthesia Drugs market, with region specific assessments and competition analysis.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on regional scale

Extensively researched competitive landscape section with profiles of major companies along with their market shares

Identification and analysis of the macro and micro factors that affect the Global General Anesthesia Drugs Market

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1 Study Deliverables
1.2 Market Definition
1.3 Study assumptions
2. Research Approach and methodology
2.1 Introduction
2.2 Analysis Methodology
2.3 Study Timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Disscussion Guide
2.4.3 Market Engineering & Econometric model
2.4.4 Expert Validation
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry trends
5.1 Current Market Senario
5.2 Porter's Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat to new entrants
5.2.4 Threat to substitute products and services
5.2.5 Competitive Rivalry within the industry
6. Market Drivers, Restraints, Challenges and Opportunities
6.1 Market Drivers
6.1.1 Increasing number of plastic and cosmetic surgeries
6.1.2 Increasing trends in dental procedures
6.1.3 Emerging economies
6.2 Market Restraint
6.2.1 To many generic products in market
6.2.2 Lack of new products
6.3 Market Opportunity
6.4 Market Challenge
7. Market Segmentation
7.1 Local Anesthetics
7.1.1 Bupivacaine
7.1.2 Ropivacaine
7.1.3 Lidocaine
7.1.4 Chloroprocaine
7.1.5 Oxethazaine
7.1.6 Prilocaine
7.1.7 Benzocaine
7.1.8 Other local anesthetics
7.2 By Application
7.2.1 Plastic Surgery
7.2.2 Cosmetics
7.2.3 Dental Anesthetics
7.2.4 Spinal anesthetics
7.2.5 Peripheral nerve block
7.2.6 Epidural
7.2.7 Interscalene block
7.2.8 Saddle block
7.2.9 Others
8. Market segmentation by Geography
8.1 North America
8.1.1 Introduction
8.1.2 United States
8.1.3 Canada
8.1.4 Mexico
8.2 Europe
8.2.1 Introduction
8.2.2 Germany
8.2.3 United Kingdom
8.2.4 France
8.2.5 Italy
8.2.6 Spain
8.2.7 Rest of Europe
8.3 Asia-Pacific (APAC)
8.3.1 Introduction
8.3.2 China
8.3.3 Japan
8.3.4 India
8.3.5 Australia & New Zealand
8.3.6 South Korea
8.3.7 Rest of Asia-Pacific
8.4 Middle East & Africa
8.4.1 GCC
8.4.2 South Africa
8.4.3 Rest of MENA
8.5 South America
8.5.1 Brazil
8.5.2 Argentina
8.5.3 Rest of South America
9. Competitive Landscape
9.1 Merger and acquisition analysis
9.2 New Product Launches
9.3 Agreements, Collaborations and Parterships
10. Company Profiles
10.1 AstraZeneca
10.2 Fresenius Kabi
10.3 Teva Pharmaceuticals
10.4 Hospira
10.5 Sagent
10.6 Mylan
10.7 Actavis
11. Future outlook for investment opportunity
12. Analyst outlook of the market
Note: Product cover images may vary from those shown
3 of 3